Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G

Immunome, Inc.

IMNMNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Nov 16, 2026Accepted Nov 16, 2026, 11:52 AM ESTFiling CIK 1472012Accession 0000902219-26-000335
Share

Structured filing — SCHEDULE 13G

primary_doc.xml

Open full document ↗

Subject company

Company
Immunome, Inc.
Company CIK
0001472012
Street
18702 North Creek Parkway,
Street (continued)
Suite 100
City
Bothell
State / country code
X1
Postal code
NA

Statement details

Security class
Common Stock
Event date
09/30/2026
Rule designation
Rule 13d-1(b)

Reporting person 1

Name
Wellington Management Group LLP
Citizenship / organization
MA
Reporting person type
HC
Aggregate amount owned
6,041,333.00
Percent of class
5.3
Sole voting power
0
Shared voting power
5,696,467
Sole dispositive power
0
Shared dispositive power
6,041,333

Reporting person 2

Name
Wellington Group Holdings LLP
Citizenship / organization
DE
Reporting person type
HC
Aggregate amount owned
6,041,333.00
Percent of class
5.3
Sole voting power
0
Shared voting power
5,696,467
Sole dispositive power
0
Shared dispositive power
6,041,333

Reporting person 3

Name
Wellington Investment Advisors Holdings LLP
Citizenship / organization
DE
Reporting person type
HC
Aggregate amount owned
6,041,333.00
Percent of class
5.3
Sole voting power
0
Shared voting power
5,696,467
Sole dispositive power
0
Shared dispositive power
6,041,333

Reporting person 4

Name
Wellington Management Company LLP
Citizenship / organization
DE
Reporting person type
IA
Aggregate amount owned
6,041,333.00
Percent of class
5.2
Sole voting power
0
Shared voting power
5,695,111
Sole dispositive power
0
Shared dispositive power
5,872,919

Item 1

Issuer

Immunome, Inc.

Principal executive office address

18702 North Creek Parkway,, Suite 100, Bothell WA

Item 2

Citizenship

Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware Wellington Management Company LLP - Delaware

Filing person

Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP Wellington Management Company LLP

Principal business or residence address

c/o Wellington Management Company LLP, 280 Congress Street, Boston MA 02210

Item 3

Not applicable indication

N

Type of filing person

HC · IA

Item 4

Percent of class

5.32

Amount beneficially owned

See the responses to Item 9 on the attached cover pages.

Sole voting power

0

Shared voting power

See the responses to Item 6 on the attached cover pages.

Sole dispositive power

0

Shared dispositive power

See the responses to Item 8 on the attached cover pages.

Item 5

Not applicable indication

Y

Item 6

Not applicable indication

N

Ownership on behalf of another person

The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows: Not Applicable.

Item 7

Not applicable indication

N

Subsidiaries

Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Wellington Group Holdings LLP - HC Wellington Investment Advisors LLP - HC Wellington Management Global Holdings, Ltd. - HC One or more of the following investment advisers (the "Wellington Investment Advisers"): Wellington Management Company LLP - IA Wellington Management Canada LLC - IA Wellington Management Singapore Pte Ltd - IA Wellington Management Hong Kong Ltd - IA Wellington Management International Ltd - IA Wellington Management Japan Pte Ltd - IA Wellington Management Australia Pty Ltd - IA The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Signature 1

Reporting person
Wellington Management Group LLP
Signed
Matthew Revell
Title
Compliance Manager
Date
11/16/2026

Signature 2

Reporting person
Wellington Group Holdings LLP
Signed
Matthew Revell
Title
Compliance Manager
Date
11/16/2026

Signature 3

Reporting person
Wellington Investment Advisors Holdings LLP
Signed
Matthew Revell
Title
Compliance Manager
Date
11/16/2026

Signature 4

Reporting person
Wellington Management Company LLP
Signed
Matthew Revell
Title
Compliance Manager
Date
11/16/2026

Filed exhibits

Company context

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA and an MAA has been validated by the EMA; IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; IM-3050, a clinical-stage FAP-targeted radioligand therapy; and IM-1340, an IND-cleared solid tumor ADC. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.

Current securities

Recent company filings

  1. S-3ASR filingNov 9, 2026
  2. S-3ASR filingNov 9, 2026
  3. 10-Q filingNov 9, 2026
  4. Results of Operations and Financial ConditionNov 9, 2026
  5. Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesOct 5, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.